JP2018516931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516931A5 JP2018516931A5 JP2017562660A JP2017562660A JP2018516931A5 JP 2018516931 A5 JP2018516931 A5 JP 2018516931A5 JP 2017562660 A JP2017562660 A JP 2017562660A JP 2017562660 A JP2017562660 A JP 2017562660A JP 2018516931 A5 JP2018516931 A5 JP 2018516931A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- binding antibody
- administered
- functional fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562170761P | 2015-06-04 | 2015-06-04 | |
| US62/170,761 | 2015-06-04 | ||
| PCT/IB2016/053242 WO2016193931A1 (en) | 2015-06-04 | 2016-06-02 | Use of il-1 beta binding antibodies to treat peripheral arterial disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516931A JP2018516931A (ja) | 2018-06-28 |
| JP2018516931A5 true JP2018516931A5 (OSRAM) | 2018-08-16 |
Family
ID=56132984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562660A Pending JP2018516931A (ja) | 2015-06-04 | 2016-06-02 | 末梢動脈疾患を処置するためのｉｌ−１ベータ結合抗体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210198356A1 (OSRAM) |
| EP (1) | EP3303388A1 (OSRAM) |
| JP (1) | JP2018516931A (OSRAM) |
| AU (1) | AU2016272900A1 (OSRAM) |
| CA (1) | CA2988055A1 (OSRAM) |
| WO (1) | WO2016193931A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2575853A (en) * | 2018-07-25 | 2020-01-29 | Robert Wotherspoon Hugh | IL-1ß binding antibody |
| EP3853225B1 (en) | 2018-09-17 | 2023-11-29 | Yungjin Pharm. Co., Ltd. | N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer |
| WO2020128636A1 (en) * | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| AU2013344796B2 (en) | 2012-11-16 | 2016-11-10 | Novartis Ag | Use of IL-1 beta binding antibodies for treating peripheral arterial disease |
-
2016
- 2016-06-02 CA CA2988055A patent/CA2988055A1/en not_active Abandoned
- 2016-06-02 AU AU2016272900A patent/AU2016272900A1/en not_active Abandoned
- 2016-06-02 WO PCT/IB2016/053242 patent/WO2016193931A1/en not_active Ceased
- 2016-06-02 EP EP16729638.3A patent/EP3303388A1/en not_active Withdrawn
- 2016-06-02 JP JP2017562660A patent/JP2018516931A/ja active Pending
-
2021
- 2021-03-17 US US17/204,622 patent/US20210198356A1/en not_active Abandoned
-
2023
- 2023-03-28 US US18/191,471 patent/US20230265182A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1696900B1 (en) | Use of treprostinil to treat ischemic lesions | |
| Dahlöf et al. | Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension) | |
| Jafarinia et al. | Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial | |
| JP2015187125A5 (OSRAM) | ||
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| JP2016502526A5 (OSRAM) | ||
| CN101287457A (zh) | Treprostinil用于治疗神经性糖尿病的足部溃疡的用途 | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2017528427A5 (OSRAM) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JP2021527128A5 (OSRAM) | ||
| JP2019533715A5 (OSRAM) | ||
| JP2021527129A5 (OSRAM) | ||
| JP2018531605A5 (OSRAM) | ||
| JP2017501154A5 (OSRAM) | ||
| RU2008135360A (ru) | Композиции и способы лечения пациентов с сердечно-сосудистыми, церебрально-васкулярными и другими сосудистыми заболеваниями | |
| RU2523412C1 (ru) | Способ лечения больных облитерирующими заболеваниям и артерий нижних конечностей | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| Wani et al. | Efficacy of Irsal-i-Alaq (Hirudotheraphy) in the Management of Venous Ulcer: A Case Report | |
| Hall et al. | Vitamin B12 and coordination exercises for combined degeneration of the spinal cord in pernicious anemia | |
| KR20230043905A (ko) | 5-메틸-1,2,4-옥사디아졸-3-일 화합물의 저용량 요법 및 제제 | |
| Henderson et al. | Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation | |
| RU2025131205A (ru) | Производные имидазотриазина в качестве модуляторов il-17 | |
| RU2025131206A (ru) | Производные имидазотриазина в качестве модуляторов il-17 |